Digital Therapeutic Manufacturer Happify Health has partnered with neuroscience pharmaceutical company Biogen to build a digital collaboration and learning platform for the treatment of multiple sclerosis.
The product will include a Happify community for people living with MS, as well as access to neurological service providers such as doctors and nurses, mental health professionals, nutritionists, and rehabilitation professionals. Biogen will provide educational content and patient care resources.
“This collaboration is one of the many ways we are focused on supporting patients by meeting them where they are. The combination of Biogen’s expertise in neuroscience and our commitment to digital healthcare, as well as Happify Health’s AI and digital therapeutic capabilities, will help create a connected and inclusive experience that allows patients to feel supported throughout the journey,” Jason Hoebaker, head of the department, said in a statement. strategic partnership and cooperation of Biogen.
“We are encouraged by the potential of this partnership to provide overall support to the MS community.”
WHY IS IT IMPORTANT
According to National Multiple Sclerosis SocietyNearly one million people in the US have multiple sclerosis. The disease can cause symptoms like numbness or tingling, weakness, difficulty walking, vision problems, and dizziness.
Happify positions collaboration as a way to improve patient care and keep them informed about their condition.
“People living with MS can find it difficult to keep up to date with the latest treatments, interpret new symptoms, or investigate changes in their health that may or may not be related to MS,” Ofer Leidner, president of Happify Health, said in a statement. .
“We provide the MS community with a solution configured to meet their specific needs, as well as opportunities to interact with experts, receive curated content, and discuss disease management with other members of the community. We are very excited to partner with Biogen on this opportunity. their leadership in the MS space.”
Happify has had partnership issues in recent months. Earlier this month, digital therapy company announced a collaboration this focuses on women’s health with Anthem soon to be rebranded as Elevance Health.
In March, Happify entered into an agreement with medical and pharmaceutical company Zuellig Pharma to commercialize two prescription digital therapeutics in Asia.
The startup also recently launched a digital program for people with psoriasis in Spain, Italy and the UK through a partnership with Barcelona-based pharmaceutical company Almirall. Happify also closed a $73 million Series D funding round in March 2021.
Biogen is also no stranger to digital health. In May it has entered into a licensing agreement with digital prescription therapy startup MedRhythms to develop and commercialize its MR-004 product, which aims to improve the mobility of people with multiple sclerosis.